Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three‐year results from the UNCOVER‐3 study
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the American Academy of Dermatology"
DOI: 10.1016/j.jaad.2018.05.032
Abstract: Background Psoriasis is a chronic disease that may require long‐term treatment. Ixekizumab (IXE), which is a high‐affinity monoclonal antibody that selectively targets interleukin 17A, is an approved therapy for patients with moderate‐to‐severe plaque psoriasis. Objective… read more here.
Keywords: uncover study; pasi score; treatment; improvement baseline ... See more keywords